 Galera Therapeutics NASDAQ:GRTX was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Wednesday, Zacks.com reports. The firm presently has a 14.00 price target on the stock. Zacks Investment Researchs price objective would suggest a potential upside of 13.09 from the companys previous close. ... 